BE528966A - - Google Patents
Info
- Publication number
- BE528966A BE528966A BE528966DA BE528966A BE 528966 A BE528966 A BE 528966A BE 528966D A BE528966D A BE 528966DA BE 528966 A BE528966 A BE 528966A
- Authority
- BE
- Belgium
- Prior art keywords
- adrenochrome
- weight
- hydroxy
- mono
- acid
- Prior art date
Links
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 claims description 49
- 239000000243 solution Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000011780 sodium chloride Substances 0.000 claims description 25
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims description 23
- 230000002439 hemostatic Effects 0.000 claims description 12
- 159000000000 sodium salts Chemical class 0.000 claims description 12
- XSXCZNVKFKNLPR-SDQBBNPISA-N Carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 claims description 8
- MNUOZFHYBCRUOD-UHFFFAOYSA-N 3-hydroxyphthalic acid Chemical group OC(=O)C1=CC=CC(O)=C1C(O)=O MNUOZFHYBCRUOD-UHFFFAOYSA-N 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 150000007857 hydrazones Chemical class 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 229960002631 carbazochrome Drugs 0.000 claims description 6
- 230000003000 nontoxic Effects 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 4
- TWBYWOBDOCUKOW-UHFFFAOYSA-N Isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims description 4
- BUWNFEVQQZTGIM-BOPFTXTBSA-N N-[(Z)-(3-hydroxy-1-methyl-6-oxo-2,3-dihydroindol-5-ylidene)amino]pyridine-4-carboxamide Chemical compound O=C1C=C2N(C)CC(O)C2=C\C1=N\NC(=O)C1=CC=NC=C1 BUWNFEVQQZTGIM-BOPFTXTBSA-N 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 159000000001 potassium salts Chemical class 0.000 claims description 2
- 206010018987 Haemorrhage Diseases 0.000 description 6
- 230000000740 bleeding Effects 0.000 description 4
- 231100000319 bleeding Toxicity 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000007659 semicarbazones Chemical class 0.000 description 3
- 229960004025 sodium salicylate Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- OCISOSJGBCQHHN-UHFFFAOYSA-N 3-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC(O)=CC2=C1 OCISOSJGBCQHHN-UHFFFAOYSA-N 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 229920002456 HOTAIR Polymers 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- -1 ammonium cations Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000000025 haemostatic Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE528966A true BE528966A (it) |
Family
ID=162108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE528966D BE528966A (it) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE528966A (it) |
-
0
- BE BE528966D patent/BE528966A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1009819A3 (fr) | Composition antiparasitaire pour le traitement et la protection des animaux de compagnie. | |
| CH630260A5 (fr) | Compositions antibiotiques a base d'une tetracycline. | |
| WO1994012171A1 (fr) | Compositions injectables a base de derives des taxanes | |
| WO1993000928A1 (fr) | Nouvelles compositions a base de derives de la classe des taxanes | |
| CH646412A5 (fr) | Procede de preparation des produits hydrosolubles a base de (+)-catechine et compositions contenant ces produits. | |
| EP1592414A1 (fr) | Formulation liquide injectable de paracetamol | |
| CH469659A (fr) | Procédé d'obtention de dérivés du tri-hydroxy-méthyl-aminométhane | |
| CH644015A5 (fr) | Solution aqueuse injectable a base d'oxytetracycline. | |
| LU83739A1 (fr) | Alpha-(3,4,5-trimethoxybenzoylthio)propionylglycine,son procede de preparation et compositions pharmaceutiques la contenant | |
| BE528966A (it) | ||
| OA11026A (fr) | Gel antimycosique à forte libération de substance active | |
| EP0080940B1 (fr) | Nouveaux dérivés de 2-phényl-morpholine et compositions thérapeutiques | |
| FR2651230A1 (fr) | Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments. | |
| EP0575481B1 (fr) | Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4 | |
| BE530472A (it) | ||
| WO1981002295A1 (fr) | Phenoxyisobutyrates de moroxydine et medicaments les contenant | |
| FR2519552A1 (fr) | Procede pour stabiliser le lysozyme dans une composition liquide ou semi-liquide, et composition stabilisee a base de lysozyme | |
| CH622023A5 (en) | Process for the preparation of a water-soluble compound based on a substituted phenylaminoalcohol | |
| BE536866A (it) | ||
| CH406194A (fr) | Procédé de préparation de sels stables de diméthylcarboxy-alkylsulfonium | |
| BE523745A (it) | ||
| BE486193A (it) | ||
| BE528056A (it) | ||
| BE561485A (it) | ||
| BE458733A (it) |